title: Anti-transforming growth factor-β therapy in patients with myelofibrosis.
authors.affiliation: The Tisch Cancer Institute.
authors.forename: John
authors.initials: J
authors.lastname: Mascarenhas
authors.forename: Timmy
authors.initials: T
authors.lastname: Li
authors.forename: Lonette
authors.initials: L
authors.lastname: Sandy
authors.forename: Carrie
authors.initials: C
authors.lastname: Newsom
authors.forename: Bruce
authors.initials: B
authors.lastname: Petersen
authors.forename: James
authors.initials: J
authors.lastname: Godbold
authors.forename: Ronald
authors.initials: R
authors.lastname: Hoffman
mesh_terms: D000368:Aged; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005076:Exanthema / Q000139:chemically induced; D005221:Fatigue / Q000139:chemically induced; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D055728:Primary Myelofibrosis / Q000188:drug therapy*; D016212:Transforming Growth Factor beta / Q000037:antagonists & inhibitors* / Q000276:immunology; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D016212:Transforming Growth Factor beta; C560928:fresolimumab